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Circular dichroismSmall-angle neutron scattering (SANS) studies have been performed to study the structural changes induced
in the membranes of vesicles prepared (by thin ﬁlm evaporation) from phospholipid and mixed
phospholipid–sterol mixtures, in the presence of different concentrations and different aggregation states
of the anti-fungal drug, amphotericin B (AmB). In the majority of the experiments reported, the lipid vesicles
were prepared with the drug added directly to the lipid dispersions dissolved in solvents favouring either
AmB monomers or aggregates, and the vesicles then sonicated to a mean size of ~100 nm. Experiments were
also performed, however, in which micellar dispersions of the drug were added to pre-formed lipid and lipid–
sterol vesicles. The vesicles were prepared using the phospholipid palmitoyloleoylphosphatidylcholine
(POPC), or mixtures of this lipid with either 30 mol% cholesterol or 30 mol% ergosterol. Analyses of the SANS
data show that irrespective of the AmB concentration or aggregation state, there is an increase in the
membrane thickness of both the pure POPC and the mixed POPC-sterol vesicles—in all cases amounting to
~4 Å. The structural changes induced by the drug's insertion into the model fungal cell membranes (as
mimicked by POPC-ergosterol vesicles) are thus the same as those resulting from its insertion into the model
mammalian cell membranes (as mimicked by POPC-cholesterol vesicles). It is concluded that the speciﬁcity of
AmB for fungal versus human cells does not arise because of (static) structural differences between lipid–
cholesterol-AmB and lipid–ergosterol-AmB membranes, but more likely results from differences in the
kinetics of their transmembrane pore formation and/or because of enthalpic differences between the two
types of sterol-AmB complexes.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Over the past decade there has been a dramatic rise in the
frequency of diagnosed fungal infections [1,2]—encompassing both
systemic infections (ascribed to increased numbers of patients
immuno-compromised through chemotherapy or HIV infection
[2,3]) and also transplant- and implant-related infections (attribut-
able to mycotic bioﬁlm development [4]). This sharp increase in
fungal infections has been accompanied by an increased frequency
with which these infections prove recalcitrant to standard anti-fungal
therapy [5–8]. There is an emerging demand, therefore, for novel anti-
fungal agents that can circumvent the pathogens' resistance. The
successful development of such novel anti-mycotics will clearly
require an appreciation of both the mechanism(s) of action of the
failed compounds and the molecular mechanism(s) underlying the
reduced susceptibility of the resistant pathogens.: +44 207 848 4800.
, a.drake@kcl.ac.uk (A.F. Drake),
S.E. Rogers),
cl.ac.uk (D.J. Barlow).
ll rights reserved.Since its discovery in the mid-1950s, one of the mainstays of the
anti-fungal armamentarium has been the polyene macrolide antibi-
otic, amphotericin B (AmB) (Fig. 1) [3]. Several recent reports,
however, have attested to the emergence of AmB-resistant strains of a
number of clinically problematic pathogenic yeasts including Candida
spp [1–8]. Now, although it has long been held that AmB exerts its
anti-fungal action through the generation of self-assembled ion
channels within the fungal cell membranes, there is no direct
structural evidence to support this hypothesis. It has been shown
that the selectivity of AmB for fungal vs. human cell membranes is
linked to the organisms' differing steroid content—with fungal cell
membranes having ergosterol and their mammalian counterparts,
cholesterol. It has been proposed (on the basis of ion and non-
electrolyte permeability studies) that AmB - and related polyene
macrolides such as nystatin - forms ion channels within bio-
membranes [9]. Models of these ion channels have been derived
based upon a consideration of the amphipathic structures of the
drugs, together with an experimental demonstration of their
cooperativity in development of the toxigenic membrane conduc-
tance (which leads to cell death through indiscriminate transfer of
ions across the cell membranes) [10]. The selective toxicity of AmB
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Fig. 1. Chemical structure of amphotericin B.
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containing fungal cell membranes compared to cholesterol-contain-
ing human cell membranes is believed to be a crucial factor in the
speciﬁcity for fungi, with the commonly held view that the ion
channels formed involve drug-sterol complexation, with complexes
involving ergosterol being strongly preferred over those involving
cholesterol [11]. Recent research, however, suggests that this
“textbook” explanation of how AmB works is only partially correct
and very oversimpliﬁed [12–16]. It has been shown, for example, that
the nature of the interaction between AmB and cell membranes is
inﬂuenced very signiﬁcantly by the concentration of drug [15,17,21–
23], the concentration of sterol [17–19,23], and the lipid composition
[20] and physical state/properties of the membrane [15,17,18].
Moreover, there is now controversy regarding the role of sterols in
the membrane—and some experiments in fact indicate that AmB may
form pores in sterol-freemembranes [20–22]. Sufﬁce to say, therefore,
that there is considerable research effort still required to determine
themolecular basis for the anti-mycotic activity of AmB and its related
polyene antibiotics such as nystatin. Without a detailed understand-
ing of the drugs' mechanism(s) of action, through which the
chemistry of the drugs can be quantitatively related to their biologicalefﬁcacy, it will prove difﬁcult to develop novel variants of the drug
which exhibit the necessary speciﬁcity, whilst also being effective
against AmB-resistant fungi.
The information required to furnish such understanding can only
be secured by using biophysical analytical techniques to probe, in a
systematic way, the interactions between the drug, sterols and lipids
at the molecular level. The ﬁrst such studies – employing a
combination of small-angle neutron scattering (SANS), X-ray diffrac-
tion and Fourier transform infrared spectroscopy – were reported by
Hereć et al. [17]. In these studies, however, the membrane interac-
tions of AmB were investigated using vesicles prepared from egg
lecithin alone—without incorporated cholesterol or ergosterol [17].
Here, we report SANS studies performed on both phospholipid and
phospholipid–sterol vesicles, as a means to securing an understanding
of how differences in a sterol's structure inﬂuence its effects on bio-
membranes, and as a means also then to explore how these
differences inﬂuence the membrane interactions of the polyene
macrolide antibiotic AmB.
2. Materials and methods
2.1. Sample preparation
All chemicals – other than those indicated below –were purchased
from Sigma-Aldrich Ltd. (Gillingham, UK) and were used as received.
Hydrogenated and deuterated phospholipids were purchased from
Avanti Polar Lipids (Alabaster, AL, USA). The dispersions of the
vesicles were prepared by means of thin ﬁlm evaporation [24]. For the
majority of the experiments detailed below, phospholipid and 2:1
phospholipid–sterol solutions were prepared in chloroform (5 mL,
Fluka, UK, Ltd., Dorset; spectroscopic grade) at a concentration of
1.25 mg/mL (or the equivalent in the case of d-lipid samples), and
were evaporated to dryness using a BUCHI 461 rotary evaporator. The
resulting h-lipid ﬁlms were then dispersed in 5 mL D2O (Aldrich, UK,
Ltd., Dorset; 99.7% D), and the corresponding d-lipid ﬁlms were
dispersed either in H2O or D2O. These aqueous lipid dispersions were
vortexed for 5 min, placed in a water bath at ambient temperature for
10 min, and ﬁnally ultrasonicated for 5 min using a probe sonicator
(Lucas Dawes Ultrasonicator Soniprobe). (The concentration of the
lipid dispersions was ~1.25 mg/mL – with the precise concentration
dependent on the particular lipid/lipid:sterol mixture used – and so
the molar ratio of water:lipid was always in excess of 30:1.)
Equivalent sets of samples were also prepared incorporating a ﬁnal
concentration of AmB in the lipid ﬁlm of 0.1 μM, 1 μM, 10 μM or
100 μM. For these latter samples, the AmB was initially prepared as a
25 mg/mL stock solution in dimethyl sulfoxide (DMSO, Fluka, UK, Ltd.,
Dorset; spectroscopic grade), and the required volume of this stock
then taken and added to the lipid or lipid:sterol solution dissolved in
chloroform or chloroform:methanol 2:1 v/v. (The latter was
employed in the case of the systems involving 10 μM and 100 μM
AmB as a precaution against aggregation of the drug.) [25]. The level
of DMSO in the ﬁnal aqueous dispersions of these AmB-containing
vesicles was always≤0.04 vol%. Other samples were also prepared
with an aqueous dispersion of AmB (containing≤0.04 vol% DMSO)
added to pre-formed lipid or lipid–sterol vesicles; for these experi-
ments the AmB and lipid (or lipid–sterol) solutions (in either D2O or
H2O) were prepared at twice the required ﬁnal concentration (viz.,
~2.5 mg/mL for the lipid, and 200 μM for the AmB), and the samples
then prepared by mixing the drug and vesicle stocks in the ratio 1:1.
For each vesicle suspension (diluted from the corresponding solution
used for SANS studies by 1 in 16) photon correlation spectroscopic
(PCS) measurements were recorded as a function of time (using a
Brookhaven Zetaplus instrument), and indicated that the dispersions
were stable (at ambient temperature) for up to 3 days (the time
required to perform the SANS experiments), showing no signiﬁcant
change in particle size or polydispersity over this period (typically
1576 F. Foglia et al. / Biochimica et Biophysica Acta 1808 (2011) 1574–1580~100 nm and ~0.15 for the POPC samples, and ~100 nm and ~0.18 for
the mixed POPC-sterol samples). For all samples, the resulting
preparations gave vesicle volume fractions≤0.005, (assuming only
ULVs of uniform diameter 100 nm) and the solvent used in
preparation caused no discernable changes in the vesicle size
distribution or stability. Note, too, that the vesicle samples were not
centrifuged following ultrasonication, because any particles shed by
the titanium probe would be far too large to interfere with the
subsequent SANS measurements.
2.2. SANS measurements and data analysis
SANS measurements were performed on the LOQ beam line at the
ISIS pulsed neutron source (STFC Rutherford Appleton Laboratory,
Didcot, UK). LOQ uses pulses of neutrons with wavelengths 2.2 to
10 Å which are separated by time-of-ﬂight and recorded at a 64 cm2,
two-dimensional 3H-CF4 detector (ORDELA Inc., Oak Ridge, USA) at
4.1 m from the sample. Wavelength-dependent corrections are made
to allow for the incident spectrum, detector efﬁciencies, and
measured sample transmissions to create a composite SANS pattern
(as described in detail in Heenan et al. [26]). This setup gives a
scattering vector Q=(4π/λ) sin (θ) range of 0.008 Å−1 to 0.22 Å−1.
Comparisons with scattering from a partially deuterated polystyrene
standard allow absolute scattering cross sections to be determined,
with an error of around 2%. Samples were placed in disk-shaped fused
silica cells of 1.0 mm (for H2O) or 2.0 mm (for D2O) path length
(Hellma UK, Ltd., Essex). All SANS measurements were recorded with
samples maintained at 298 K, using a 12-mm-diameter neutron
beam. Backgrounds from pure H2O or D2O were subtracted. All ﬁtting
procedures included ﬂat background corrections to allow for any
mismatch in the incoherent and inelastic scattering between sample
and solvent. Fitted background levels were always checked to
determine whether they were of a physically reasonable magnitude.
Given that PCS measurements indicated that the vesicles in all
samples were ~100 nm diameter, and in each case, therefore, could
safely be assumed to involve a mixture of predominantly multi-
lamellar with some unilamellar vesicles, the SANS data were
modelled as previously [27,28], assuming mixtures of (isolated)
inﬁnite planar sheets and 1-dimensional paracrystalline stacks of
these [29–31], with the various model parameters optimised using
Heenan's FISH software [32].Table 1
Structural parameters obtained through simultaneous ﬁts to the three sets of SANS data obta
sterol mixtures in the absence and presence of amphotericin (AmB). Symbols used are as d
Lipid(s) Solventa [AmB]/μM Lb/Å
POPC CHCl3 0 36.5 (0.3)
0.1 39.7 (0.2)
1 40.1 (0.3)
CHCl3:MeOH 10 39.5 (0.3)
100 39.5 (0.3)
POPC-Chol CHCl3 0 41.4 (0.3)
0.1 43.7 (0.6)
1 43.7 (0.3)
CHCl3:MeOH 10 43.7 (0.3)
100 43.7 (0.2)
POPC-Erg CHCl3 0 40.7 (0.3)
0.1 43.7 (0.4)
1 43.7 (0.3)
CHCl3:MeOH 10 43.7 (0.2)
100 43.7 (0.6)
a For L, the ﬁgures in parentheses show standard errors; for D, the uncertainties repor
polydispersity.
b Samples prepared using only lipid or lipid–sterol mixtures with AmB at a concentration
10 μM and 100 μM were prepared in CHCl3:MeOH—as a means to ensure that the drug was
c Dashes in the ﬁnal two columns indicate systems for which SANS measurements were3. Results and discussion
For each of the pure lipid and mixed lipid–sterol systems
investigated, the SANS data were recorded (at 298 K) in the absence
of amphotericin (AmB) and in the presence of different ﬁnal
concentrations of AmB in the range 0.1–100 μM (the cmc of the
drug being 1 μM [33]). For each system (with the exception of the
system involving 0.1 μM AmB, where only the h-lipid system was
studied), the SANS data were obtained under three different H/D
contrasts provided by h-lipid vesicles dispersed in D2O, and d-lipid
vesicles dispersed in D2O or H2O. Simultaneous model ﬁts to these
data were obtained as described previously [30,31] using the FISH
program [32]. The parameters reﬁned in the model ﬁtting included
the sample background scattering, the proportions of unilamellar
vesicles (ULVs) and multilamellar vesicles (MLVs), the thickness of
the vesicle lamellae (L, Å; taken to be the same for the ULVs and
MLVs), the d-spacing of the MLVs (D, Å) and the polydispersity on the
d-spacing (σ(D)/D). Three other parameters involved in the SANS
models were initially treated as adjustable - and were thus ﬁtted
along with the six parameters listed above - but preliminary analyses
revealed that their ﬁtted values showed insigniﬁcant variation from
dataset to dataset; in the ﬁnal analyses, therefore, these parameters
were constrained as ﬁxed. These ﬁxed parameters (and their
constrained values) included the polydispersity on the thickness of
the vesicle lamellae (σ(L)/L; taken as zero – but of practical necessity
input as 10−6), themean lamellarity of theMLVs in the sample (M; 3),
and the Lorentz correction factor (Rσ; 236 Å) [28]. The ﬁtted
parameter values for all systems studied are summarised in Table 1,
and illustrative SANS data together with the corresponding model ﬁts
are shown in Figs. 2–4.
For the pure POPC vesicle preparations, the model ﬁts to the SANS
data (Fig. 2) indicate a mixture of ULVs and MLVs, with a lamellar
thickness, L=36.5±0.2 Å (Table 1). For comparison, we note that
Kučerka et al. [34] give the Luzatti thickness for oriented (hydrated)
POPC bilayer stacks as 36.8 Å. For the MLVs in these pure POPC
samples, the d-spacing has a ﬁtted value of 56.1 Å, with a statistical
uncertainty of ±0.3 Å. Here, however, as with all of the systems
described below, the uncertainty in the estimated d-spacing is not
given just by the statistical uncertainty in the position of the Gaussian
peak (D), but by the convolution of this with thewidth of the Gaussian
distribution (σ(D)). The true uncertainty in the d-spacing for the POPCined for vesicle dispersions prepared from the various phospholipid and phospholipid–
escribed in the text.
Db/Å Ratio of ULV:MLV surface areasc
h− in D2O d− in D2O d− in H2O
56.1±8 2.1 1.7 3.1
59.8±3 1.9 – –
61.9±3 2.1 1.6 2.8
59.4±3 1.8 1.5 0.9
60.0±3 1.6 1.6 1.9
56.1±3 2.1 1.9 1.6
62.4±4 1.5 – –
62.0±4 1.6 1.3 3.4
62.4±4 1.6 1.8 2.2
62.4±4 1.7 1.6 1.7
56.5±4 2.1 2.2 1.4
62.4±4 2.6 – –
62.4±4 1.8 1.5 2.0
62.4±4 2.2 1.8 3.9
62.4±4 1.7 1.5 0.4
ted represent the convolution of the statistical error on D and the value of the ﬁtted
of 0–1 μMwere prepared in CHCl3, whilst those incorporating AmB at concentrations of
not aggregated (see Supplementary information).
not recorded.
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Fig. 3. SANS data and model ﬁts for POPC-cholesterol vesicles in the absence of AmB
(upper panel) and with incorporation of 100 μM AmB in the lipid ﬁlm used in
preparation of the vesicle dispersion (lower panel). Q is the neutron momentum
transfer, in Å−1. The structural parameters for the model ﬁts shown are presented in
Table 1.
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Fig. 2. SANS data and model ﬁts for POPC vesicles in the absence of AmB (upper panel)
and with the incorporation of 100 μM AmB in the lipid ﬁlm used in preparation of the
vesicle dispersion (lower panel). Q is the neutron momentum transfer, in Å−1. The
structural parameters for the model ﬁts shown are presented in Table 1.
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SANS data cannot be satisfactorily modelled assuming ULVs alone—
the ﬁtting for all systems warranting consideration of a mixed
population of MLVs and ULVs, the precision on the MLV d-spacing is
rather poor (for the pure POPC MLVs, 49–65 Å). Such imprecision is
sadly inevitable given the absence of a clear Bragg peak in the SANS
proﬁle. It is encouraging nevertheless to note that this d-spacing range
does span the values previously reported for POPC vesicles and
multilayers (typically, 54–65 Å [34–37]).
Using the bilayer thickness data together with the lipid molecular
volumes (vL, taken from Greenwood et al. [38]; see Table 2) the mean
lipid interfacial area can be calculated as a0=2vL/L [39]. For the POPC
vesicle bilayers, such calculations give a0=68.8±0.4 Å2, which is
consistent with the value reported by Kučerka et al. [34] on the basis
of X-ray diffraction measurements on oriented POPC bilayer stacks
(viz., a0=68.3 Å2).
When the POPC vesicles are prepared in the presence of 30 mol%
sterol, the SANS data (cf. Figs. 3, 4) model ﬁts (Table 1) show that the
bilayer thickness increases by ~4 Å for added ergosterol, and ~5 Å for
added cholesterol, although - given the experimental uncertainties of±0.3 Å - the difference for the two sterols here is probably not
signiﬁcant. These results are consistent with the ﬁndings of other
workers, with the 2H-NMR studies of Nezil and Bloom [40] giving a 4 Å
increase in thickness of the hydrophobe region of POPC bilayers in the
presence of 30 mol% cholesterol.
Using the thickness estimates for the mixed lipid–sterol bilayers
we can again calculate the effective lipid interfacial molecular areas,
a0. In this case, however, it is necessary to employ molecular volumes
computed as the mean of the lipid and sterol (Table 2 [38,41]),
weighted according to their mole fraction in the mixture. For the
POPC-cholesterol and POPC-ergosterol bilayers, we have vL=
(0.7 × 1256)+ (0.3 × 623)=1066 Å3, and vL= (0.7 × 1256)+
(0.3×608)=1062 Å3, respectively. The corresponding mean molec-
ular areas are then obtained as a0≈(2×1064)/41=52 Å2. Now, if the
meanmolecular areas are computed instead using the weightedmean
of the bilayer interfacial areas for the pure lipid and that for (chole)
sterol (27 Å2; [42]) we get a0=59.6 Å2 for the POPC-sterol bilayers.
Accordingly, the (known) condensing effect of the sterols on the
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Fig. 4. SANS data and model ﬁts for POPC-ergosterol vesicles in the absence of AmB
(upper panel) and with incorporation of 100 μM AmB in the lipid ﬁlm used in
preparation of the vesicle dispersion (lower panel). Q is the neutron momentum
transfer, in Å−1. The structural parameters for the model ﬁts shown are presented in
Table 1.
Table 3
Structural parameters obtained through model ﬁtting of SANS data recorded at various
times after injection of amphotericin (to a ﬁnal concentration of 100 μM) into pre-
formed h-lipid vesicle dispersions prepared (in D2O) from the various phospholipid and
phospholipid–sterol mixtures. Symbols used are as described in the text, and the ﬁgures
in parentheses show standard errors.
Lipid(s) [AmB]/μM Time from
injection
La/Å Da/Å Ratio of ULV:MLV
surface areas
h− in D2O
1578 F. Foglia et al. / Biochimica et Biophysica Acta 1808 (2011) 1574–1580phospholipid bilayers amounts to a 18% condensation, which is close
to the ﬁgure of 12% reported for the cholesterol-induced condensation
of POPC monolayers maintained at a surface pressure of 30 mN/m
[43].
When amphotericin (AmB) is added to the lipid ﬁlms in the course
of preparing the vesicles, the effect on the vesicle bilayer structure
seems independent of the vesicle composition. In the case of the SANS
data for the vesicles prepared from POPC alone (Fig. 3), the model ﬁts
(Table 1) indicate that the presence of AmB seems to cause a smallTable 2
Volumes and densities of POPC, ergosterol, cholesterol, and amphotericin (quoted for
the temperature indicated).
Compound Temperature/K Volume/Å3 Density/g cm−3
POPC [38] 303 1256 0.995
Cholesterol [38] 298 623 0.94
Ergosterol [41] 298 608 0.92
Amphotericin B [50] 298 983 1.56increase in the bilayer thickness, from ~37 Å to ~40 Å. This change is
consistent with the structural/spectroscopic studies reported by
Umegawa et al. [44] which indicated the formation of AmB aggregates
in POPC membranes; they also accord with the earlier observations
made in H+ release experiments which show that phospholipid
vesicles are sensitive to AmB even in the absence of sterols [45].
Although Hereć et al. [46] reported no change in bilayer thickness
caused by the addition of AmB to egg yolk phosphatidylcholine
vesicles, this was only for AmB concentrations at or below 1 mol%, and
the authors do note that at an AmB concentration of 5 mol%, there is a
signiﬁcant change in the lipid acyl chain ordering which is consistent
with an incorporation of the drug into the hydrophobe layer of the
membrane. (In the samples studied here – assuming that all of the
added drug remains in the vesicle membranes - the use of 100 μM
AmB equates to an addition of the drug at 3 mol%.)
If either (30 mol%) cholesterol or ergosterol is included in the
POPC bilayers, the SANS data (cf. Figs. 3 and 4) model ﬁts (Table 1)
indicate that the addition of AmB causes the same increase in
thickness as seen with POPC vesicles - amounting to ~3 Å. This
increase in thickness might arise because (1) AmB simply embeds
itself within the lipid head groups and lies more or less ﬂat on the
membrane surface, or (2) AmB inserts itself vertically into the outer
leaﬂet of the bilayer with its amino-sugar head group protruding
slightly above the level of the phosphocholine head groups. On the
basis of the SANS data modeling performed here, there is no direct
way to distinguish these two situations. However, by analogywith the
situation found to pertain for membrane active anti-microbial
peptides (for example, protegrin [47]), it might be expected that the
binding of the polyene macrolide AmB within the lipid head groups
would actually lead to a disturbance of the lipid packing and thence to
membrane thinning and not - as seen here – membrane thickening.
Also, given that AmB induces the same changes in the vesicle
membranes regardless of whether the drug is added at a concentra-
tion below or above its cmc (1 μM [33]), it seems most likely that the
increase in vesicle membrane thickness arises due to a vertical
insertion of the drug into themembrane. If this were not to be the case
then the AmB micelles would ﬁrst need to dissociate in order to
liberate AmB monomers which could then migrate and spread across
the membrane surface, and such a situation seems energetically very
unlikely. Moreover, a vertical insertion of AmB into the membrane is
clearly indicated by the ﬂuorescence measurements presented by
Silva et al. [48] which showed signiﬁcant sterol structure-dependent
differences in the transmembrane ion currents induced by the related
polyene macrolide antibiotic, nystatin, and also by the DSC and FT-IRPOPC 0 0 37.6 (0.3) 51.4±3 3.1
10 39 min 39.5 (0.4) 60.0±3 1.6
100 25 h 15 min 39.5 (0.3) 60.0±3 1.7
POPC-Chol 0 0 42.0 (0.3) 57.4±3 1.6
10 36 min 44.0 (0.3) 62.0±4 1.6
100 24 h 18 min 44.0 (0.4) 62. 0±4 1.6
POPC-Erg 0 0 41.0 (0.4) 55.2±4 2.2
10 39 min 44.8 (0.3) 62.3±4 2.0
100 24 h 44.0 (0.6) 63. 0±4 2.0
a For L, the ﬁgures in parentheses show standard errors; for D, the uncertainties
reported represent the convolution of the statistical error on D and the value of the
ﬁtted polydispersity.
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between the hydrophobes of AmB and ergosterol.
It is important to note, however, that in the SANS experiments
described above, the AmB (for reasons of simplicity) was incorporated
directly into the vesicle bilayers through its inclusion in the lipid ﬁlms
used in preparation of the vesicles. It is perfectly possible, therefore,
that the structural information derived in these experiments could be
entirely irrelevant to the in vivo situation—where the drug partitions
into the cell membranes from its dispersion (as monomers and/or
aggregates) in the bulk. In order to determine whether such
membrane-bulk AmB interactions would lead to the formation of
the samemembrane structures as reported above, we thus performed
a more limited set of experiments in which the drug was mixed with
pre-formed lipid and lipid–sterol vesicles, and the SANS proﬁles of
these systems were monitored and modelled as a function of time
after mixing. The model ﬁts to these SANS curves (with the values of
the ﬁtted parameters summarised in Table 3) clearly show that the
structures of the membranes resulting from the interaction of AmB
with pre-formed vesicles seem to be exactly the same as found for
those where the drug was embedded in the membranes at the time of
vesicle formation. Indeed, the changes in bilayer thickness and multi-
layer d-spacings seem to be complete within one hour of mixing of the
drug and vesicles (the shortest measurement interval that was
possible given the experimental conditions; Table 3)—and again the
resulting membrane structures are no different for the POPC-
cholesterol and the POPC-ergosterol membranes.
4. Conclusions
The speciﬁcity of AmB for fungal versus human cells would thus
seem to arise not because of any static structural differences between
lipid–cholesterol-AmB and lipid–ergosterol-AmB membranes, but
more likely because of differences in the kinetics of their transmem-
brane pore formation and/or because of enthalpic differences
between the two types of sterol-AmB complexes, which thenmanifest
as differences in the life-times and/or distributions of the two types of
complex within the plane of the membrane.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
doi:10.1016/j.bbamem.2011.02.012.
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